Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT03239873, this PHASE3 trial focuses on Varicella and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 19 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
19 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Jun 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
▶ Show 14 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Completed PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Completed PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Completed PHASE3
-
May 2019 — Sep 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .